ASND Ascendis Pharma A/S

105.66
+2.3  (+2%)
Previous Close 103.36
Open 103.63
Price To Book 6.24
Market Cap 5,023,626,255
Shares 47,545,204
Volume 33,447
Short Ratio
Av. Daily Volume 214,426

NewsSee all news

  1. Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

    – TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of achondroplasia on children

  2. Ascendis Pharma A/S Announces Three Investor Presentations in September

    COPENHAGEN, Denmark, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

BLA filing due 1H 2020.
TransCon hGH
Growth hormone deficiency in children
Phase 2 top-line data due 4Q 2019.
TransCon
Hypoparathyroidism
Phase 2 trial has been initiated.
TransCon CNP - ACcomplisH
Achondroplasia

Latest News

  1. Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

    – TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of achondroplasia on children

  2. Ascendis Pharma A/S Announces Three Investor Presentations in September

    COPENHAGEN, Denmark, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced